Where does Hydra Biosciences, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Hydra Biosciences, LLC ranks #9,520 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Hydra Biosciences, LLC hold?

Hydra Biosciences, LLC holds 33 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Hydra Biosciences, LLC's Innovation Score?

Hydra Biosciences, LLC has an Innovation Score of 33.2 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Hydra Biosciences, LLC focus on?

Hydra Biosciences, LLC's top technology area is C07D (Heterocyclic Compounds) with 31 patents, ranking #263 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Hydra Biosciences, LLC's patent grant rate increasing or decreasing?

Hydra Biosciences, LLC's recent grant velocity is -77% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Hydra Biosciences, LLC's patents?

Hydra Biosciences, LLC's patents average 15.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Hydra Biosciences, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Hydra Biosciences, LLC

USPTO PatentsView assignee record - 33 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hydra ranks #9,520 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 6 technology areas.

#9,520
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.2/100): 15.1
avg claims per patent: -77%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9520 · US Corporation #9,520 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 33 grants
UPPER-Q #9,520/49,997
PHOTO-FINISH HashiCorp
CPC-NARROW C07D · 6 areas
INNOV-THIN 33.2/100
CLAIMS-RICH 15.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -77% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: HashiCorp (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hydra’s 33.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.2 pts (37%) Velocity 3.3 pts (10%) Breadth 8.7 pts (26%) Claim depth 9.1 pts (27%)

Qualcomm Incorporated · highest

85
Deca · near

33
Gima S p A · near

33
Hydra Biosciences · this assignee

33
Lexion Medical · near

33
Tri State Distribution · near

33
3D Lighting… · lowest

7

What this shows Hydra's Innovation Score is 33.2/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Hydra?

Each dot is one of Hydra’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hydra’s own 15.1 claims/patent is ABOVE the 12.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Hydra vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hydra's grants concentrate

Hydra Biosciences, LLC is a focused PatentsView assignee: 6 CPC subclasses with 93.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (9 grants) versus a trough of 1 in 2020. By volume, Hydra sits between Hyundai America Technical Center Inc. and ISORG.

Hydra's three-year grant acceleration

Hydra Biosciences, LLC shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hyundai America T…

33
Hashicorp

33
Hefei Core Storage

33
Hotalux

33
IHI Aerospace

33
IHI Charging Syst…

33
Iq-analog

33
Isorg

33
Hydra Biosciences ◀

33

What this shows Hydra holds 33 patents at rank #9,521, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Hydra

By rank, the assignees closest to #9,521 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Hydra's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hydra, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Hydra ranks #263 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Deca Technologies Inc. 33 Tri State Distribution, Inc. 33 Gima S.p.A. 33 Lexion Medical, LLC 33

Hydra's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Hydra Biosciences, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	18.2%
2016	9	27.3%
2017	4	12.1%
2018	4	12.1%
2019	3	9.1%
2020	1	3.0%
2021	2	6.1%
2022	1	3.0%
2023	1	3.0%
2024	1	3.0%
2025partial year	1	3.0%

Which technologies does Hydra Biosciences, LLC patent most?

C07D - Heterocyclic Compounds 31

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 23

C07K - Peptides 2

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hydra Biosciences, LLC's patent record in context - here's where to go next.

Hydra Biosciences, LLC's lead technology class is C07D (Heterocyclic Compounds), 93.9% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #9,520 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Hydra Biosciences, LLC against Hyundai America Technical Center Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.